Stem cell-derived exosomes for ischemic stroke: a conventional and network meta-analysis based on animal models
Stammzellabgeleitete Exosomen bei ischämischem Schlaganfall: konventionelle und Netzwerk-Metaanalyse auf Basis von Tiermodellen
Frontiers in Pharmacology · 23.10.2024 · 15
DOI: 10.3389/fphar.2024.1481617 ↗Auf einen Blick
38 randomisierte Tierexperimente zeigen: Stammzellabgeleitete Exosomen senkten Hirninfarktvolumen und mNSS. Nach Netzwerk-Metaanalyse war die intravenöse Gabe am günstigsten.
Fragestellung
Wie wirksam sind stammzellabgeleitete Exosomen bei ischämischem Schlaganfall, und welche Applikationsstrategie ist am günstigsten?
Methode
Systematische Übersicht mit konventioneller und Netzwerk-Metaanalyse; Suche in PubMed, Web of Science, Embase, Cochrane Library und Scopus bis 31. Dezember 2023.
Ergebnisse
38 randomisierte kontrollierte Tierexperimente. Intravenös senkte Hirninfarktvolumen (%) und mNSS, intranasal das Hirninfarktvolumen (%), intrazerebral die mNSS. BMSC-Exos waren bei intravenöser Gabe am besten.
Einschränkungen
Weitere hochwertige randomisierte kontrollierte Tierexperimente und direkte Vergleichsdaten sind nötig.
Schlussfolgerung der Autor:innen
Die Metaanalyse zeigte intravenöse Gabe als beste Applikationsroute, BMSC-Exos als beste Exosomenart und nennt allogene bzw. xenogene Exosomen als am wirksamsten für unterschiedliche Endpunkte.
Kernaussagen
- 38 randomisierte Tierexperimente wurden eingeschlossen.
- Intravenös war in der Netzwerk-Metaanalyse die beste Applikationsroute.
- BMSC-Exos waren bei intravenöser Gabe am besten.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 23.10.2024. Verfasst von Kangli Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Themen: Schlaganfall
Abstract (Originalsprache)
Objective
We aimed to evaluate the efficacy of stem cell-derived exosomes for treating ischemic stroke and to screen for the optimal administration strategy.
Methods
We searched PubMed, Web of Science, Embase, Cochrane Library, and Scopus databases for relevant studies published from their inception to 31 December 2023. Conventional and network meta-analyses of the routes of administration, types, and immune compatibility of stem cell-derived exosomes were performed using the cerebral infarct volume (%) and modified neurological severity score (mNSS) as outcome indicators.
Results
A total of 38 randomized controlled animal experiments were included. Conventional meta-analysis showed that compared with the negative control group: intravenous administration significantly reduced the cerebral infarct volume (%) and mNSS; intranasal administration significantly reduced the cerebral infarct volume (%); and intracerebral administration significantly reduced the mNSS. Adipose-derived mesenchymal stem cell-derived exosomes (ADSC-Exos), bone marrow mesenchymal stem cell-derived exosomes (BMSC-Exos), dental pulp stem cell-derived exosomes (DPSC-Exos) and neural stem cell-derived exosomes (NSC-Exos) significantly reduced the cerebral infarct volume (%) and mNSS; Endothelial progenitor cell-derived exosomes (EPC-Exos), embryonic stem cell-derived exosomes (ESC-Exos), induced pluripotent stem cell-derived exosomes (iPSC-Exos) and neural progenitor cell-derived exosomes (NPC-Exos) significantly reduced the cerebral infarct volume (%); Umbilical cord mesenchymal stem cell-derived exosomes (UCMSC-Exos) significantly reduced the mNSS; and there was no significant difference between urogenital stem cell-derived exosomes (USC-Exos) and negative controls. Engineered modified exosomes had better efficacy than unmodified exosomes. Both allogeneic and xenogeneic stem cell-derived exosomes significantly reduced the cerebral infarct volume (%) and the mNSS. The network meta-analysis showed that intravenous administration was the best route of administration for reducing the cerebral infarct volume (%) and mNSS. Among the 10 types of stem cell-derived exosomes that were administered intravenously, BMSC-Exos were the best type for reducing the cerebral infarct volume (%) and the mNSS. Allogeneic exosomes had the best efficacy in reducing the cerebral infarct volume (%), whereas xenogeneic stem cell-derived exosomes had the best efficacy in reducing the mNSS.
Conclusion
This meta-analysis, by integrating the available evidence, revealed that intravenous administration is the best route of administration, that BMSC-Exos are the best exosome type, that allogeneic exosomes have the best efficacy in reducing the cerebral infarct volume (%), and that xenogeneic exosomes have the best efficacy in reducing mNSS, which can provide options for preclinical studies. In the future, more high-quality randomized controlled animal experiments, especially direct comparative evidence, are needed to determine the optimal administration strategy for stem cell-derived exosomes for ischemic stroke. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42024497333 , PROSPERO, CRD42024497333
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
- The First Clinical Medical College of Henan University of Chinese Medicine, Zhengzhou, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Xu, K., Zhao, X., He, Y., Guo, H., & Zhang, Y. (2024). Stem cell-derived exosomes for ischemic stroke: a conventional and network meta-analysis based on animal models. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1481617
Vancouver
Xu K, Zhao X, He Y, Guo H, Zhang Y. Stem cell-derived exosomes for ischemic stroke: a conventional and network meta-analysis based on animal models. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1481617
BibTeX
@article{Xu2024,
author = {Xu, Kangli and Zhao, Xiaohui and He, Yuxuan and Guo, Hongxin and Zhang, Yunke},
title = {Stem cell-derived exosomes for ischemic stroke: a conventional and network meta-analysis based on animal models},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1481617}
}
EUVIMED